

✂ Please cut along the dotted lines before submitting to a pharmacy.

Date Required: \_\_\_\_\_ Ship To: Home Office Other: \_\_\_\_\_

**PATIENT INFORMATION**

Patient Name: \_\_\_\_\_  
 Address: \_\_\_\_\_  
 City, State, Zip: \_\_\_\_\_  
 Home Phone: \_\_\_\_\_  
 Cell Phone: \_\_\_\_\_  
 Date of Birth: \_\_\_\_\_ Gender: \_\_\_\_\_  
 Emergency Contact: \_\_\_\_\_ Phone: \_\_\_\_\_

**PRESCRIBER INFORMATION**

Prescriber Name: \_\_\_\_\_  
 Address: \_\_\_\_\_  
 City, State, Zip: \_\_\_\_\_  
 Phone: \_\_\_\_\_  
 Fax: \_\_\_\_\_  
 DEA #: \_\_\_\_\_ NPI #: \_\_\_\_\_  
 Contact Person: \_\_\_\_\_

**INSURANCE INFORMATION (Please attach the front and back of insurance and prescription drug card.)**

Primary Insurance: \_\_\_\_\_ ID: \_\_\_\_\_ Group: \_\_\_\_\_  
 Secondary Insurance: \_\_\_\_\_ ID: \_\_\_\_\_ Group: \_\_\_\_\_  
 Prescription Card: \_\_\_\_\_ ID: \_\_\_\_\_ BIN: \_\_\_\_\_ PCN: \_\_\_\_\_

**To better serve your patient and facilitate insurance authorization, please complete the pertinent sections:**

**DIAGNOSIS**

G70.00 Myasthenia Gravis without (acute) exacerbation  
 G70.01 Myasthenia Gravis with (acute) exacerbation

Clinical/Progress notes with supporting diagnosis

H&P

Patient's demographics, including insurance information

Please attach original prescription orders

Current medications: \_\_\_\_\_

Previous therapies: eculizumab rituximab IVIG

oral corticosteroids non-steroidal ISTs

Previous live vaccine: \_\_\_\_\_ Date: \_\_\_\_\_

**MEDICAL HISTORY**

Patient Weight: \_\_\_\_\_ kg lbs Height: \_\_\_\_\_ cm in

Allergies: \_\_\_\_\_

Line Access: Peripheral PICC Port

Delivery Method: Infusion Pump Other: \_\_\_\_\_

Therapy Start Date: \_\_\_\_\_ Therapy End Date: \_\_\_\_\_

Nursing Coordination:

Pharmacy to coordinate home health

nursing visit as necessary: Yes No

Home health nursing coordination not necessary. Reason:

MD office to administer to patient

Home health nursing already coordinated

**PRESCRIPTION INFORMATION**

**Vyvgart® Prescription:**

10mg/kg body weight weekly for 4 doses. (Once weekly x 4 weeks.) Maximum dose: 1.2gm. Subsequent treatment cycles may be administered based on clinical evaluation and no sooner than 50 days from the start of the previous treatment cycle.

**Vyvgart® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Prescription:**

1,008 mg/11,200 units (5.6mL) subcutaneous injection over 30-90 seconds once weekly for 4 weeks. Subsequent treatment cycles based on clinical evaluation; no sooner than 50 days from the start of the previous treatment cycle.  
 To be administered by a healthcare professional with 30 minutes post observation period.

**ORDERS/OTHER MEDICATIONS**

▶ **Orders are initiated**

▶ Infusion supplies as per protocol

▶ Anaphylaxis Kit orders as per protocol

**Flush Protocol (For Vyvgart® intravenous infusion only)**

NaCl 0.9% 5mL

Heparin 10 units per mL

NaCl 0.9% 10mL

Heparin 100 units per mL

Other: \_\_\_\_\_

**ADDITIONAL COMMENTS:**

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

